Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

News Daily News

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

Yael L. Maxwell

May 21, 2020

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths

News Daily News

New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths

April 10, 2020

News Daily News

COVID-19 Should Not Guide Use of ACE Inhibitors/ARBs, Heart Societies Say

March 17, 2020

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

October 23, 2019

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

News Daily News

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Michael O'Riordan

October 18, 2019

Trial Points to Possible Benefit of Intensive BP-Lowering to Stave Off Recurrent Stroke

News Daily News

Trial Points to Possible Benefit of Intensive BP-Lowering to Stave Off Recurrent Stroke

July 29, 2019

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

News Daily News

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Marcus A. Banks

July 12, 2019

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

April 03, 2019

FDA: Some Tainted Losartan Must Remain on US Market to Maintain Adequate Access for Patients

News Daily News

FDA: Some Tainted Losartan Must Remain on US Market to Maintain Adequate Access for Patients

March 21, 2019

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

News Daily News

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

March 04, 2019

Quality of CAD Care Varies by Type of Medicare Coverage

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

February 20, 2019

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

News Daily News

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

September 13, 2018

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

News Daily News

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

March 29, 2018

Low BP Tied to Poor Outcomes in Hospitalized Patients With HFpEF

News Daily News

Low BP Tied to Poor Outcomes in Hospitalized Patients With HFpEF

February 20, 2018

As Hypertension Sweeps China, Awareness, Treatment, and Control Remain Poor

News Daily News

As Hypertension Sweeps China, Awareness, Treatment, and Control Remain Poor

October 26, 2017

Generic ARBs Linked to Increased Adverse Events

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

News Daily News

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Michael O'Riordan

June 05, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.